NASDAQ · INKT

MiNK Therapeutics, Inc.

Closing price · Nov 13, 2026 $9.34

Latest quarter · ended Sep 30, 2026

Sales slipped and cash got weaker

descriptionFiled Nov 12, 2026

Revenue growth

—Sales for the quarter: $200K

Cash from operationsWorse

−$1.28M

Dec '24Sep '26

vs. −$941K a year ago

Share countDiluting

+9.4%

Dec '24Sep '26

5.13M shares vs. 4.69M a year ago

Numbers come from the company's own 10-Q and 10-K reports filed with the SEC. Each bar is one quarter, oldest on the left. The colored bar is the latest. Hover over or tap a bar to see its number.

Smart money pulse

What insiders and funds are doing

Selling Insiders: as of Nov 13 Funds: as of Jun 30, 2026

info
6 real insider sales in 12 months. $120K in total, not counting planned sales.

−100 means everyone selling, +100 everyone buying. This is data, not advice.

How the Pulse works

Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.

Who owns it

30 funds report owning INKT, up from 23

Holdings as of Jun 30, 2026

New10

Added6

Held11

Trimmed3

Sold out3

Insider trades · last 12 months

Real buys and sales

● Open-market buy● Open-market sale

Last 6 months. A wider screen shows 12.

Showing 6 real trades. Hidden: 22 stock grants, 1 option exercise. Those happen on a schedule and say little about what an insider thinks. Bigger dot means a bigger trade.

Real trades, newest first

Oct 12 Jennifer Buell CEO, Director Open-market sale $73.3K 6,938 sh at $10.56 Sold 9% of stake

Jun 4 Barbara Ryan Director Open-market sale $19.1K 1,500 sh at $12.76 Sold 6% of stake

Mar 10 Barbara Ryan Director Open-market sale $20K 1,300 sh at $15.40 Sold 6% of stake

Mar 9 Barbara Ryan Director Open-market sale $2.03K 200 sh at $10.17 Sold 1% of stake

Mar 2 Barbara Ryan Director Open-market sale $1.08K 100 sh at $10.83 Sold 1% of stake

Feb 27 Barbara Ryan Director Open-market sale $4.34K 400 sh at $10.86 Sold 2% of stake

Showing every filing. Dashed circles are routine: grants, tax withholding, option exercises and planned sales.

Top holders

Biggest funds in INKT

As of Jun 30, 2026

Fund	Owns	Value	Change
Vanguard Capital Management LLC	1.3%	$803K	+16%
DNB Asset Management AS	1.1%	$645K	New
Longbow Finance SA	0.3%	$195K	Same
Geode Capital Management, LLC	0.3%	$182K	−10%
Citadel Advisors LLC	0.3%	$180K	New

"Owns" is shares reported divided by shares outstanding.